PharmaShots | Incisive News in 3 Shots

Subscribe Now

UCB

UCB Reports P-III Open-Label Extension Study Results of Fintepla (fenfluramine) for Lennox-Gastaut Syndrome

UCB Reports P-III Open-Label Extension Study Results of Fintepla (fenfluramine) for Lennox-Gastaut Syndrome

November 24, 2022

UCB Reports the US FDA Acceptance of NDA and EMA’s Validation of MAA for Zilucoplan to Treat Generalized Myasthenia Gravis

UCB Reports the US FDA Acceptance of NDA and EMA’s Validation of MAA for Zilucoplan to Treat Generalized Myasthenia Gravis

November 15, 2022

UCB Presents New Three-Year P-III (BE BRIGHT) OLE Study Results of Bimekizumab for Plaque Psoriasis at EADV 2022

UCB Presents New Three-Year P-III (BE BRIGHT) OLE Study Results of Bimekizumab for Plaque Psoriasis at EADV 2022

September 8, 2022

Top 20 Immunology Companies Based on 2021 Immunology Segment Revenue

Top 20 Immunology Companies Based on 2021 Immunology Segment Revenue

August 11, 2022

UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axSpA) and Ankylosing Spondylitis (AS)

UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axS...

May 24, 2022

UCB Presents Efficacy and Safety Results of Zilucoplan and Rozanolixizumab in P-III (RAISE) & (MycarinG) Study for Generalized Myasthenia Gravis at MGFA 2022

UCB Presents Efficacy and Safety Results of Zilucoplan and Rozanolixizumab in P-III (RAISE) & (MycarinG) Study for Generalized Mya...

May 11, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us